Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LMX1A antisense RNA 2 (LMX1A-AS2) is a non-coding RNA molecule transcribed antisense to the LMX1A gene locus. As an antisense lncRNA, it could regulate the expression of LMX1A— which encodes a transcription factor essential for neural development—through mechanisms such as transcriptional interference, RNA-RNA interactions, or modulation of chromatin state[4]. While antisense lncRNAs have broad implications in regulation and disease, there is presently no published functional or clinical data specific to LMX1A-AS2. Its classification as a target is primarily molecular, not therapeutic; there are no established drugs, biomarkers, or disease associations relating directly to LMX1A-AS2 as of the current literature[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LMX1A antisense RNA 2 (LMX1A-AS2).